US4054645A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Radiodiagnostic complexes employing fluorine-containing tin reducing agents
Assignee: 3M Co
•
Filing: 1976-08-24
•
Granted: 1977-10-18
•
Expires: 1996-08-24
Abstract
Abstract Radiodiagnostic agents for use in mammalian bodies comprising a radiocomplex which is the reaction product of Tc99m-pertechnetate ion, a diagnostic ligand and a tin (II) reducing agent selected from the group consisting of SnF 2 , MSnF 3 , MSn 2 F 5 and mixtures thereof, wherein M is NH 4 , Na, K, Li, Rb or Cs. Radiocomplex precursor compositions and methods of making the radiocomplex and radiodiagnostic agents are described.
Inventors
- 👤 Brian K. Hill
- 👤 Verna M. Kubik
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-10-26 02:36
CPC Classifications
A; A61; A61K; A61K51/00; A61K51/02; A61K51/04; A61K51/0402; A61K51/0489; A61K2123/00
Claims Analysis
Total Claims: 17
Claim 1
Independent Claim
81 words
An intravenously injectable diagnostic solution for use in mammalian bodies which is an aqueous solution comprising a target-specific radiocomplex, said radiocomplex comprising the reaction product of an aqueous mixture of (a) Tc99m-pertechnetate ion, (b) a target-specific diagnostic ligand, and (c) a tin (II) reducing agent for said pertechnetate ion selected from the group consisting of SnF 2 , MSnF 3 and MSn 2 F 5 , and mixtures thereof, wherein M is NH 4 , Na, K, Li, Rb or Cs.
Claim 2
Dependent Claim
81 words
An intravenously injectable diagnostic solution for use in mammalian bodies which is an aqueous solution comprising a target-specific radiocomplex, said radiocomplex comprising the reaction product of an aqueous mixture of (a) Tc99m-pertechnetate ion, (b) a target-specific diagnostic ligand, and (c) a tin (II) reducing agent for said pertechnetate ion selected from the group consisting of SnF 2 , MSnF 3 and MSn 2 F 5 , and mixtures thereof, wherein M is NH 4 , Na, K, Li, Rb or Cs.
Claim 3
Dependent Claim
17 words
A diagnostic solution according to claim 1 wherein said aqueous solution comprises sterile, aqueous, isotonic saline solution.
Claim 4
Dependent Claim
17 words
A radiodiagnostic solution according to claim 1 having a pH in the range of 2 to 7.
Claim 5
Dependent Claim
48 words
A diagnostic solution according to claim 1 wherein said radiocomplex comprises the reaction product of a diagnostically sufficient amount of Tc99m-pertechnetate ion and a molar excess of reducing agent, and wherein the ratio of moles of diagnostic ligand to moles of reducing agent is greater than about 1:1.
Claim 6
Dependent Claim
25 words
A diagnostic solution according to claim 1 wherein said diagnostic ligand is selected from the group consisting of sodium pyrophosphate, 2,3-dimercaptosuccinic acid and 6,8-dihydrothioctic acid.
Claim 7
Dependent Claim
74 words
An aseptic, stable pharmaceutical composition for the preparation of an intravenously injectable radiodiagnostic solution containing a target-specific radiocomplex for mammalian bodies, said composition being a radiocomplex precursor composition comprising a mixture of a target-specific diagnostic ligand and a fluorine-containing tin (II) compound selected from the group consisting of SnF 2 , MSnF 3 , MSn 2 F 5 , and mixtures thereof wherein M is NH 4 , Na, K, Li, Rb or Cs.
Claim 8
Dependent Claim
74 words
An aseptic, stable pharmaceutical composition for the preparation of an intravenously injectable radiodiagnostic solution containing a target-specific radiocomplex for mammalian bodies, said composition being a radiocomplex precursor composition comprising a mixture of a target-specific diagnostic ligand and a fluorine-containing tin (II) compound selected from the group consisting of SnF 2 , MSnF 3 , MSn 2 F 5 , and mixtures thereof wherein M is NH 4 , Na, K, Li, Rb or Cs.
Claim 9
Dependent Claim
14 words
A composition according to claim 6 wherein said radiocomplex precursor is a freeze-dried solid.
Claim 10
Dependent Claim
19 words
A composition according to claim 6 wherein said radiocomplex precursor is contained in a sterile, aqueous isotonic saline solution.
Claim 11
Dependent Claim
26 words
A composition according to claim 6 wherein the ratio of moles of diagnostic ligand to moles of fluorine-containing tin (II) compound is greater than about 1:1.
Claim 12
Dependent Claim
33 words
A composition according to claim 9 wherein said fluorine-containing tin (II) compound is present in an amount in excess of the theoretical amount required to reduce a diagnostically sufficient amount of Tc99m-pertechnetate ion.
Claim 13
Dependent Claim
23 words
A composition according to claim 6 wherein said target-specific diagnostic ligand is selected from the group consisting of sodium pyrophosphate and 2,3-dimercaptosuccinic acid.
Claim 14
Dependent Claim
92 words
A process for the preparation of a target-specific radiocomplex for use in mammalian body diagnosis comprising a. reducing, in aqueous solution, Tc-99m-pertechnetate ion to a 99m-technetium species having an oxidation state greater than zero but less than +7 with a reducing agent comprising a fluorine-containing tin (II) compound selected from the group consisting of SnF 2 , MSnF 3 , MSn 2 F 5 , and mixtures thereof, wherein M is NH 4 , Na, K, Li, Rb or Cs, b. complexing said reduced 99m-technetium species with a target specific radiodiagnostic ligand.
Claim 15
Dependent Claim
92 words
A process for the preparation of a target-specific radiocomplex for use in mammalian body diagnosis comprising a. reducing, in aqueous solution, Tc-99m-pertechnetate ion to a 99m-technetium species having an oxidation state greater than zero but less than +7 with a reducing agent comprising a fluorine-containing tin (II) compound selected from the group consisting of SnF 2 , MSnF 3 , MSn 2 F 5 , and mixtures thereof, wherein M is NH 4 , Na, K, Li, Rb or Cs, b. complexing said reduced 99m-technetium species with a target specific radiodiagnostic ligand.
Claim 16
Dependent Claim
43 words
A process according to claim 12 wherein said tin (II) compound and said diagnostic ligand are prepared in kit form as a freeze-dried mixture in an aseptically sealed vial and wherein an aqueous solution containing said Tc-99m-pertechnetate ion is injected into said vial.
Claim 17
Dependent Claim
25 words
A process according to claim 12 wherein said target-specific diagnostic ligand is selected from the group consisting of sodium pyrophosphate, 6,8-dihydrothioctic acid and 2,3-dimercaptosuccinic acid.
References Cited (Backward Citations)
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1980-10-17 | 1981-04-18 | 1981-10-18 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1984-10-17 | 1985-04-18 | 1985-10-18 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 1988-10-17 | 1989-04-18 | 1989-10-18 | $7700.00 | Window Closed / Lapsed |